ClinicalTrials.gg
RecruitingNCT07522398APTE-OAUpdated Sep 17, 2026

Acute Power Training Effects in Older Adults

An interventional study of Power Training at Different Fatigue Levels in Muscle Power, Functional Performance and Older Adults (65 Years and Older), sponsored by Hasselt University. Recruiting at 1 site in Belgium. Open to participants aged 65 Years to 85 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-17.

Sponsored by Hasselt University · Not applicable, Interventional, and Prevention

From the registry’s dates

  • Started Apr 2026; still recruiting 6 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
42
Allocation
Randomized
Ages
65 Years to 85 Years
Sex
All
01

Study summary

The goal of this clinical trial is to learn how older adults respond to power training when the level of fatigue during exercise is different. Power training means performing fast movements with moderate loads to improve strength, power and mobility.

The main questions the study aims to answer are:

  • How does the level of fatigue during power training acutely affect strength, movement, and muscle function?
  • How does it affect recovery, muscle soreness, and how hard the exercise feels?

Researchers will compare three power-training sessions with different fatigue levels to see which approach may be safest and most effective for older adults.

Participants will be healthy older adults aged 65 to 85 years. Each participant will complete three supervised exercise sessions on a leg press machine. The sessions will take place about one week apart.

During the study, participants will:

  • Perform power training on a pneumatic leg press machine
  • Complete strength and mobility tests before and after exercise
  • Provide small blood samples to measure body responses to exercise
  • Rate how hard the exercise feels
  • Report muscle soreness for up to two days after exercise

The results may help researchers design safer and more effective power-training programs to improve strength, mobility, and recovery in older adults.

02

Conditions studied

  • Muscle Power
  • Functional Performance
  • Older Adults (65 Years and Older)
  • Neuromuscular Function
  • Physiological Responses
  • Healthy Older Adults

Keywords

  • Power Training
  • Older Adults
  • Aging
  • Muscle Power
  • Velocity Loss
  • Resistance Training
  • Neuromuscular Function
  • Functional Performance
  • Physiological Responses
  • Exercise Fatigue
03

In context

Lead sponsor

Hasselt University is the lead sponsor of 204 studies on the registry; 31 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
65 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Participants must:

  • Be 65 to 85 years old.
  • Be able to live independently and perform everyday activities without help.
  • Not have regularly done resistance or strength training in the past year.
  • Be able to understand study instructions and communicate in the study language.
  • Have a recent statement from their treating physician confirming that their heart and blood vessels are healthy enough to safely take part in this study.

Exclusion criteria

Exclusion criteria

Participants will not be eligible if they have any of the following:

  • Unstable heart disease, neurological disease, acute infection, or fever.
  • Use of non-steroidal anti-inflammatory drugs (NSAIDs), such as ibuprofen, in the 5 days before the study.
  • Use of whey protein, casein, or amino acid supplements in the month before the study.
  • Acute or chronic injuries to the legs or lower body muscles.
  • Any injury or condition that prevents safe leg extension exercises.
  • Recent lower-limb joint replacement (less than 6 months ago).
  • Dependence on walking aids.
  • Current participation in another interventional trial.
05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
42 participants (estimated)

Study arms

  • Experimental
    Low-Fatigue Power Training (10% velocity loss)

    Participants perform a single supervised session of power training on a pneumatic leg press, consisting of 4 sets. During the exercise, movement speed is continuously monitored. In this arm, the exercise set will be stopped when movement speed decreases by 10% compared with the fastest repetition, which corresponds to a low level of fatigue (small amount of repetitions).

    Behavioral: Power Training at Different Fatigue Levels

  • Experimental
    Moderate Fatigue Power Training (30% velocity loss)

    Participants perform a single supervised session of power training on a pneumatic leg press, consisting of 4 sets. During the exercise, movement speed is continuously monitored. In this arm, the exercise set will be stopped when movement speed decreases by 30% compared with the fastest repetition, which corresponds to a moderate level of fatigue (more repetitions, performed closer to muscle failure).

    Behavioral: Power Training at Different Fatigue Levels

  • Experimental
    Cluster-Set Power Training (10% Velocity Loss)

    Participants perform a single supervised session of power training on a pneumatic leg press. In this arm, the exercise is organized into 4 cluster sets. A cluster set consists of small groups of repetitions separated by short rest periods within the set. Participants will perform clusters of 3-4 repetitions with 20 seconds of rest between clusters. During the exercise, movement speed is continuously monitored. Each cluster will be performed within the range of 10% velocity loss compared with the fastest repetition, which corresponds to a low level of fatigue. Clusters will continue until the total number of repetitions matches the training volume (amount of total repetitions) reached in the 30% velocity loss condition. This design allows participants to complete a similar total training volume as in the moderate fatigue condition, while maintaining lower fatigue, enabling researchers to separate the effects of exercise volume from the effects of fatigue.

    Behavioral: Power Training at Different Fatigue Levels

Interventions

  • BehavioralPower Training at Different Fatigue Levels

    Participants perform supervised power-training exercise on a pneumatic leg press. Each participant completes three exercise sessions, each separated by approximately one week. In each session, participants perform 4 sets of leg press exercise under different fatigue conditions: A) Exercise sets are terminated when movement velocity decreases by 10%. B) Exercise sets are terminated when movement velocity decreases by 30%. C) Exercise sets are terminated at 10% velocity loss, with total work matched to the 30% condition.

    Also known as: Power Training at Different Velocity Loss Thresholds, Power Training at Different Velocity-Based Training Doses

06

What researchers measure

Primary outcomes

  1. Maximum Voluntary Contraction (MVC)

    Maximum voluntary contraction (MVC) will be assessed to determine the maximum force-generating capacity of the leg extensors using an isokinetic dynamometer (Humac Norm). Simultaneously, muscle activity will be recorded using surface electromyography (EMG; Delsys EMG system). Primary outcome metric: Peak torque (Nm) obtained from three maximal isometric trials recorded on the dynamometer, combined with EMG amplitude (µV) to quantify muscle activation. Interpretation: Higher torque values indicate greater knee extensor strength. EMG amplitude reflects the level of muscle activation during maximal voluntary effort. Interpretation: Higher force values indicate greater leg muscle strength. EMG values indicate the level of muscle activation during the maximal effort.

    Time frame: Measurements will be taken before exercise (baseline), 5 minutes after each training session, and 24 hours after each session.

Secondary outcomes

  1. Rate of Torque Development (RTD)

    Rate of torque development (RTD) will be assessed to determine how quickly participants can generate torque with their leg extensors. This will be measured using an isokinetic dynamometer (Humac Norm), which records joint torque, alongside surface electromyography (EMG; Delsys EMG system), which measures muscle activation. This parameter provides insight into neuromuscular responses to different levels of power training-induced fatigue. Metric: Peak rate of torque development (Nm/s) calculated from three maximal trials, together with EMG amplitude (µV). RTD will be calculated as the slope of the torque-time curve over a specified time interval (e.g., 0-100ms, 100-200 ms).

    Time frame: Measurements will be taken before exercise (baseline), 5 minutes after each training session, and 24 hours after each session.

  2. Muscle Activity

    Muscle activity will be assessed by recording the electrical signals of the leg muscles during the leg press exercise using surface electromyography (sEMG; Delsys EMG system). This method enables quantification of muscle activation and fatigue-related changes in neuromuscular function. Surface electrodes will be placed on three key thigh muscles: the vastus lateralis, vastus medialis, and biceps femoris. Metric: EMG amplitude (µV), derived from the recorded electrical signals, representing the level of muscle activation during exercise.

    Time frame: Measurements will be taken before exercise (baseline), during exercise session (mean value across the full session), 5 minutes post exercise, and 24 hours post exercise (3 exercise sessions, 1 week apart)

  3. Strength Training Data: Mean Movement Velocity

    Mean concentric movement velocity (meter per second (m/s)) recorded during each leg press (exercise) repetition using the Keiser A400 Leg Press.

    Time frame: During each exercise session (mean values across the full session) (3 Sessions ; ~1 week apart)

  4. Strength Training Data: Power

    Mean mechanical power (Watts (W)) produced during each leg press repetition recorded by the Keiser A400 Leg Press.

    Time frame: During each exercise session (mean value across the full session) (3 Sessions ; ~1 week apart)

  5. Strength Training Data: Total Number of Repetitions

    Total number of repetitions (count) completed during each exercise session on the leg press.

    Time frame: During each exercise session (mean value across the full session) (3 Sessions ; ~1 week apart)

  6. Muscle Oxygenation

    Muscle oxygenation will be assessed to determine oxygen availability in the thigh muscle (vastus lateralis) during and after exercise using near-infrared spectroscopy (NIRS). In addition, a vascular occlusion test will be performed to evaluate muscle oxygen extraction and the recovery kinetics of oxygenation following transient blood flow restriction. Metric: Muscle oxygen saturation (%; e.g., SmO₂), as well as reoxygenation rate and amplitude following occlusion.

    Time frame: Baseline (pre-exercise), continuously during each exercise session, 5 minutes post-exercise, and 24 hours post-exercise (for each of the 3 sessions, 1 week apart)

  7. Blood Lactate

    Small blood sample will be taken to measure lactate, in millimoles per liter analysed through standard laboratory tests, including Enzyme-Linked Immunosorbent Assay (ELISA).

    Time frame: Measurements will be taken at baseline and immediately post exercise session (3 sessions, 1 week apart)

  8. Blood Gas

    A Small blood sample will be taken to measure blood gas levels (blood oxygen/carbon dioxide levels) using standard laboratory tests, including Enzyme-Linked Immunosorbent Assay (ELISA).

    Time frame: Measurements will be taken at baseline and immediately post exercise session (3 sessions, 1 week apart).

  9. Creatine Kinase (CK)

    Small blood samples will be taken to measure creatine kinase (CK), an enzyme that increases in the blood when muscles are damaged or stressed. Metric: CK concentration in units per liter (U/L).

    Time frame: Measurements will be taken at Baseline and 24 hours after each exercise session.

  10. Functional Performance: Five-Repetition Sit-to-Stand Test

    Five-Repetition Sit-to-Stand (5xSTS) test: Participants stand up from a chair repeatedly. An inertial measurement unit (DynaPort MoveTest, McRoberts, The Hague, NL) measures speed (meters per second (m/s)), movement duration (s) , and power (W).

    Time frame: Measurements will be taken at Baseline, immediate post exercise and 24 hours after each exercise session.

  11. Functional Performance: Counter Movement Jump

    Countermovement Jump (CMJ): Participants jump vertically from a standing position. Jump height (cm), force (Nm), and power (W) are measured using KINVENT force plates.

    Time frame: Measurements will be taken at Baseline, immediate post exercise and 24 hours after each exercise session.

  12. Functional Performance: Stair Ascent test

    Stair Ascent Test (SA): Participants climb a set of stairs while wearing an inertial measurement unit (DynaPort MoveTest, McRoberts, The Hague, NL), which measures speed (m/s), movement duration (s), distance (cm), and power (W).

    Time frame: Measurements will be taken at Baseline, immediate post exercise and 24 hours after each exercise session.

  13. Functional Performance: 30-s Sit-to-Stand Test

    30-Second Sit-to-Stand (30sSTS) Tests: Participants stand up from a chair repeatedly. An inertial measurement unit (DynaPort MoveTest, McRoberts, The Hague, NL) measures speed (m/s), movement duration (s), and power (W).

    Time frame: Measurements will be taken at Baseline, immediate post exercise and 24 hours after each exercise session.

  14. Perceived Exertion

    Perceived exertion will be assessed using the OMNI Resistance Exercise Scale (OMNI-RES). Participants will rate their level of effort after each exercise set during the leg press sessions. The scale ranges from 1 (no exertion at all) to 10 (maximum effort), with higher scores indicating greater perceived exertion.

    Time frame: Assessed after each exercise set during each exercise session (mean value across the full session) (3 Sessions ; ~1 week apart)

  15. Delayed Onset Muscle Soreness (DOMS)

    Delayed onset of muscle soreness (DOMS) will be assessed using a Visual Analog Scale (VAS). Participants will rate perceived soreness in the leg muscles on a scale from 0 (no soreness) to 10 (worst possible soreness), with higher scores indicating greater muscle soreness.

    Time frame: Ratings will be collected at baseline, 24 hours after exercise, and 48 hours after exercise using a remote survey.

07

Study locations

1 of 1 sites recruiting
  • REVAL - Faculty of Rehabilitation Sciences
    Diepenbeek, Flanders 3590, Belgium
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Pseudonymazed participant data, including study measurements and outcomes, along with relevant supporting documents (e.g., study protocol, statistical analysis plan). Data will be shared via a Data Transfer Agreement (DTA). Access may be provided through a secure repository such as FAIRVault.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

Time frame: Beginning upon publication until 5 years after the publication of results.

Access criteria: Only qualified researchers affiliated with recognized academic or research institutions will be eligible. Researchers must submit a formal request describing the purpose and planned analyses. The research proposal must relate to legitimate scientific questions consistent with the original study aims. The proposed statistical methods must be clearly described. Researchers submit a data access request through the study's contact point or the FAIRVault platform. Once approved, they will sign a Data Transfer Agreement (DTA) before receiving access to the data. All requests will be reviewed by the study team or designated independent reviewers to ensure the research is appropriate, the data will be handled responsibly, and privacy protections are met.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Apr 2026 (actual). Primary completion is estimated for Jan 2027, 9 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 25, 2026
First posted
Apr 13, 2026
StartActual
Apr 20, 2026
Primary completionEst.
Jan 2027
CompletionEst.
Jan 2027
Last update
Sep 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07522398
Lead sponsor
Hasselt University
Responsible party
Evelien Van Roie (Prof. Dr. Evelien Van Roie, Hasselt University) — Principal investigator
First posted
Apr 13, 2026
Start date
Apr 20, 2026
Primary completion
Jan 2027 (estimated)
Completion
Jan 2027 (estimated)
Last update
Sep 17, 2026

Study contacts

Max Riesbeck, Master of Science
Contact
max.riesbeck@uhasselt.be
+32 11 26 84 93
Evelien Van Roie, PhD
Contact
evelien.vanroie@uhasselt.be
+3211269062
Evelien Van Roie, PhD
principal investigator · Hasselt University, Faculty of Rehabilitation Sciences
Bruno Tassignon, PhD
principal investigator · Hasselt University, Faculty of Rehabilitation Sciences

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion